Table 1.
Summary of population characteristics
| Variable | |
|---|---|
| Median age, years (range) | 58 (22-79) |
| Sex, n (%) | |
| Male | 61 (80.3) |
| Female | 15 (19.7) |
| Histology, n (%) | |
| Clear-cell | 57 (75) |
| Type 1 papillary | 4 (5.3) |
| Type 2 papillary | 7 (9.2) |
| Chromophobe | 3 (3.9) |
| Other | 5 (6.6) |
| IMDC prognostic group, n (%) | |
| Good | 19 (25) |
| Intermediate | 33 (43.4) |
| Poor | 14 (18.4) |
| Unknown | 10 (13.2) |
| Line before cabozantinib, n (%) | |
| First | 6 (7.9) |
| Nivolumab/ipilimumab + nivolumab | 35 (46.1) |
| Sunitinib | 5 (6.6) |
| Axitinib | 16 (21.1) |
| Everolimus | 3 (3.9) |
| Sorafenib | 4 (5.3) |
| ICI + TKI | 6 (7.9) |
| Other TKI (tivozanib, crizotinib) | 2 (2.6) |
| Median line of treatment with cabozantinib (range) | 3 (1-10) |
| Cabozantinib starting dose, n (%) | |
| 60 mg daily | 46 (64) |
| 40 mg daily | 25 (35) |
| 20 mg daily | 1 (1) |
| Median dose intensity, mg (IQR) | 40 (40-60) |
| Mean Ctrough, ng/ml (SD) | 597.7 (363.9) |
| Median Ctrough, ng/ml (IQR) | 500.2 (365.5-742.5) |
| Mean Cl/F, l/h (SD) | 2.5 (1.2) |
| Median Cl/F, l/h (IQR) | 2.3 (1.7-3.2) |
| Mean AUC, μg h/ml (SD) | 20.9 (11.1) |
| Median AUC, μg h/ml (IQR) | 18 (13.8-25.5) |
| Mean time from day 1, cycle 1 to blood draw, weeks (SD) | 50 (45.8) |
| Median time from day 1, cycle 1 to blood draw, weeks (IQR) | 38.3 (13.4-69.1) |
| Mean serum albumin, g/l (SD) | 38.2 (4.5) |
| Mean total serum protein, g/l (SD) | 66.8 (7.5) |
| Mean Ctrough at 60 mg daily, ng/ml (SD) | 667 (375) |
| Median Ctrough at 60 mg daily, ng/ml (IQR) | 564 (402-777) |
| Mean Ctrough at 40 mg daily, ng/ml (SD) | 565 (283) |
| Median Ctrough at 40 mg daily, ng/ml (IQR) | 477 (366-649) |
AUC, area under the curve; Cmeas, measured blood concentration; Ctrough, residual blood concentration; Cl/F, apparent clearance; ICI, immune checkpoint inhibitor; IMDC, International Metastatic RCC Database Consortium; IQR, Interquartile range; SD, standard deviation; TKI, tyrosine kinase inhibitor.